Page last updated: 2024-10-24

candesartan and Malignant Melanoma

candesartan has been researched along with Malignant Melanoma in 3 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Tchernev, G2
Muhailan, M1
Al-Shbool, G1

Other Studies

3 other studies available for candesartan and Malignant Melanoma

ArticleYear
NEIGHBOURING MELANOMAS AND DYSPLASTIC NEVUS DEVELOPING SIMULTANEOUSLY AFTER CANDESARTAN INTAKE: NITROSAMINE CONTAMINATION/ AVAILABILITY AS MAIN CAUSE FOR SKIN CANCER DEVELOPMENT AND PROGRESSION.
    Georgian medical news, 2023, Issue:336

    Topics: Dysplastic Nevus Syndrome; Humans; Melanoma; Nitrosamines; Skin Neoplasms

2023
THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND ТHE SUBSEQUENT SKIN CANCER DEVELOPMENT
    Georgian medical news, 2023, Issue:337

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih

2023
Pseudo-Wellens' Syndrome Temporally Associated With Immune Check Point Inhibitors Use.
    The American journal of the medical sciences, 2020, Volume: 359, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplast

2020